메뉴 건너뛰기




Volumn 39, Issue 10, 2014, Pages 465-474

Feedback and redundancy in receptor tyrosine kinase signaling: Relevance to cancer therapies

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BOSUTINIB; CERITINIB; CETUXIMAB; CRENOLANIB; CRIZOTINIB; DACOMITINIB; DASATINIB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NERATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PONATINIB; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; RAPAMYCIN DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; TARGET OF RAPAMYCIN KINASE;

EID: 84922781885     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.08.010     Document Type: Review
Times cited : (129)

References (101)
  • 1
    • 0037025173 scopus 로고    scopus 로고
    • Cancer. Addiction to oncogenes - the Achilles heal of cancer
    • Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297:63-64.
    • (2002) Science , vol.297 , pp. 63-64
    • Weinstein, I.B.1
  • 2
    • 84862999938 scopus 로고    scopus 로고
    • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    • Misale S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
    • (2012) Nature , vol.486 , pp. 532-536
    • Misale, S.1
  • 3
    • 84863000299 scopus 로고    scopus 로고
    • The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
    • Diaz L.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
    • (2012) Nature , vol.486 , pp. 537-540
    • Diaz, L.A.1
  • 4
    • 77950809059 scopus 로고    scopus 로고
    • A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
    • Sharma S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
    • (2010) Cell , vol.141 , pp. 69-80
    • Sharma, S.V.1
  • 5
    • 0035902180 scopus 로고    scopus 로고
    • Oncogenic kinase signalling
    • Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
    • (2001) Nature , vol.411 , pp. 355-365
    • Blume-Jensen, P.1    Hunter, T.2
  • 6
    • 34248583886 scopus 로고    scopus 로고
    • MAP kinase signalling pathways in cancer
    • Dhillon A.S., et al. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
    • (2007) Oncogene , vol.26 , pp. 3279-3290
    • Dhillon, A.S.1
  • 7
    • 2342445635 scopus 로고    scopus 로고
    • The JAK/STAT signaling pathway
    • Rawlings J.S., et al. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117:1281-1283.
    • (2004) J. Cell Sci. , vol.117 , pp. 1281-1283
    • Rawlings, J.S.1
  • 8
    • 0034644539 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
    • (2000) Cell , vol.103 , pp. 211-225
    • Schlessinger, J.1
  • 9
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien S.G., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348:994-1004.
    • (2003) N. Engl. J. Med. , vol.348 , pp. 994-1004
    • O'Brien, S.G.1
  • 10
    • 33845444046 scopus 로고    scopus 로고
    • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker B.J., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
    • (2006) N. Engl. J. Med. , vol.355 , pp. 2408-2417
    • Druker, B.J.1
  • 11
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw A.T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
    • (2013) N. Engl. J. Med. , vol.368 , pp. 2385-2394
    • Shaw, A.T.1
  • 12
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
    • (2010) N. Engl. J. Med. , vol.362 , pp. 2380-2388
    • Maemondo, M.1
  • 13
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    • Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
    • (2012) Lancet Oncol. , vol.13 , pp. 239-246
    • Rosell, R.1
  • 14
    • 84884736973 scopus 로고    scopus 로고
    • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    • Sequist L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013, 31:3327-3334.
    • (2013) J. Clin. Oncol. , vol.31 , pp. 3327-3334
    • Sequist, L.V.1
  • 15
    • 84892997539 scopus 로고    scopus 로고
    • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    • Wu Y.L., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:213-222.
    • (2014) Lancet Oncol. , vol.15 , pp. 213-222
    • Wu, Y.L.1
  • 16
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
    • (2001) N. Engl. J. Med. , vol.344 , pp. 783-792
    • Slamon, D.J.1
  • 17
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer C.E., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
    • (2006) N. Engl. J. Med. , vol.355 , pp. 2733-2743
    • Geyer, C.E.1
  • 18
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
    • (2011) N. Engl. J. Med. , vol.364 , pp. 2507-2516
    • Chapman, P.B.1
  • 19
    • 84885229945 scopus 로고    scopus 로고
    • Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer
    • Herrera-Abreu M.T., et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013, 3:1058-1071.
    • (2013) Cancer Discov. , vol.3 , pp. 1058-1071
    • Herrera-Abreu, M.T.1
  • 20
    • 84860540538 scopus 로고    scopus 로고
    • Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
    • Migliardi G., et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 2012, 18:2515-2525.
    • (2012) Clin. Cancer Res. , vol.18 , pp. 2515-2525
    • Migliardi, G.1
  • 21
    • 84890520181 scopus 로고    scopus 로고
    • Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    • Ganesan P., et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol. Cancer Ther. 2013, 12:2857-2863.
    • (2013) Mol. Cancer Ther. , vol.12 , pp. 2857-2863
    • Ganesan, P.1
  • 22
    • 78649723255 scopus 로고    scopus 로고
    • PLX4032 in metastatic colon cancer patients with mutant BRAF tumors
    • abstract
    • Kopetz S., et al. PLX4032 in metastatic colon cancer patients with mutant BRAF tumors. J. Clin. Oncol. 2010, 28(Supplement):3534. abstract.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 3534
    • Kopetz, S.1
  • 23
    • 79958026380 scopus 로고    scopus 로고
    • The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
    • Mendoza M.C., et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36:320-328.
    • (2011) Trends Biochem. Sci. , vol.36 , pp. 320-328
    • Mendoza, M.C.1
  • 24
    • 84870825008 scopus 로고    scopus 로고
    • JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
    • Britschgi A., et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
    • (2012) Cancer Cell , vol.22 , pp. 796-811
    • Britschgi, A.1
  • 25
    • 84867405669 scopus 로고    scopus 로고
    • Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
    • Kim S.M., et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 2012, 11:2254-2264.
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 2254-2264
    • Kim, S.M.1
  • 26
    • 77952800807 scopus 로고    scopus 로고
    • Receptor tyrosine kinase coactivation networks in cancer
    • Xu A.M., Huang P.H. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 2010, 70:3857-3860.
    • (2010) Cancer Res. , vol.70 , pp. 3857-3860
    • Xu, A.M.1    Huang, P.H.2
  • 27
    • 79953207364 scopus 로고    scopus 로고
    • Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
    • Garrett J.T., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5021-5026.
    • (2011) Proc. Natl. Acad. Sci. U.S.A. , vol.108 , pp. 5021-5026
    • Garrett, J.T.1
  • 28
    • 84859409756 scopus 로고    scopus 로고
    • Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
    • McDonagh C.F., et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11:582-593.
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 582-593
    • McDonagh, C.F.1
  • 29
    • 84884162850 scopus 로고    scopus 로고
    • Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors
    • Kirouac D.C., et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 2013, 6:ra68.
    • (2013) Sci. Signal. , vol.6 , pp. ra68
    • Kirouac, D.C.1
  • 30
    • 84877593565 scopus 로고    scopus 로고
    • De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients
    • Akhavan D., et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013, 3:534-547.
    • (2013) Cancer Discov. , vol.3 , pp. 534-547
    • Akhavan, D.1
  • 31
    • 73649102105 scopus 로고    scopus 로고
    • Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
    • Turke A.B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
    • (2010) Cancer Cell , vol.17 , pp. 77-88
    • Turke, A.B.1
  • 32
    • 84878862323 scopus 로고    scopus 로고
    • Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
    • Bardelli A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.
    • (2013) Cancer Discov. , vol.3 , pp. 658-673
    • Bardelli, A.1
  • 33
    • 80052793410 scopus 로고    scopus 로고
    • A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
    • Sasaki T., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.
    • (2011) Cancer Res. , vol.71 , pp. 6051-6060
    • Sasaki, T.1
  • 34
    • 84856999699 scopus 로고    scopus 로고
    • Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
    • 120ra117
    • Katayama R., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012, 4:120ra117.
    • (2012) Sci. Transl. Med. , vol.4
    • Katayama, R.1
  • 35
    • 77954586493 scopus 로고    scopus 로고
    • Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
    • Benedettini E., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 2010, 177:415-423.
    • (2010) Am. J. Pathol. , vol.177 , pp. 415-423
    • Benedettini, E.1
  • 36
    • 40449113978 scopus 로고    scopus 로고
    • Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
    • Shattuck D.L., et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
    • (2008) Cancer Res. , vol.68 , pp. 1471-1477
    • Shattuck, D.L.1
  • 37
    • 84868273967 scopus 로고    scopus 로고
    • Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
    • Henjes F., et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 2012, 1:e16.
    • (2012) Oncogenesis , vol.1
    • Henjes, F.1
  • 38
    • 67651174452 scopus 로고    scopus 로고
    • Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
    • Hughes J.B., et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol. Cancer Ther. 2009, 8:1885-1892.
    • (2009) Mol. Cancer Ther. , vol.8 , pp. 1885-1892
    • Hughes, J.B.1
  • 39
    • 84858268381 scopus 로고    scopus 로고
    • Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    • Gonzalez-Angulo A.M., et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin. Proteomics 2011, 8:11.
    • (2011) Clin. Proteomics , vol.8 , pp. 11
    • Gonzalez-Angulo, A.M.1
  • 40
    • 84884167635 scopus 로고    scopus 로고
    • The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells
    • Meyer A.S., et al. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 2013, 6:ra66.
    • (2013) Sci. Signal. , vol.6 , pp. ra66
    • Meyer, A.S.1
  • 41
    • 80051597880 scopus 로고    scopus 로고
    • Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta
    • Bielen A., et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta. Mol. Cancer Ther. 2011, 10:1407-1418.
    • (2011) Mol. Cancer Ther. , vol.10 , pp. 1407-1418
    • Bielen, A.1
  • 42
    • 34248591612 scopus 로고    scopus 로고
    • Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
    • Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
    • (2007) Oncogene , vol.26 , pp. 3291-3310
    • Roberts, P.J.1    Der, C.J.2
  • 43
    • 84893249799 scopus 로고    scopus 로고
    • PI3K and cancer: lessons, challenges and opportunities
    • Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13:140-156.
    • (2014) Nat. Rev. Drug Discov. , vol.13 , pp. 140-156
    • Fruman, D.A.1    Rommel, C.2
  • 44
    • 33947594129 scopus 로고    scopus 로고
    • Hyperactive Ras in developmental disorders and cancer
    • Schubbert S., et al. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
    • (2007) Nat. Rev. Cancer , vol.7 , pp. 295-308
    • Schubbert, S.1
  • 45
    • 79960051265 scopus 로고    scopus 로고
    • Therapeutic strategies for targeting ras proteins
    • Gysin S., et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
    • (2011) Genes Cancer , vol.2 , pp. 359-372
    • Gysin, S.1
  • 46
    • 84888639050 scopus 로고    scopus 로고
    • K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
    • Ostrem J.M., et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
    • (2013) Nature , vol.503 , pp. 548-551
    • Ostrem, J.M.1
  • 47
    • 84878401236 scopus 로고    scopus 로고
    • Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling
    • Zimmermann G., et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.
    • (2013) Nature , vol.497 , pp. 638-642
    • Zimmermann, G.1
  • 48
    • 84859410770 scopus 로고    scopus 로고
    • Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
    • Hayes D.N., et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin. Cancer Res. 2012, 18:2056-2065.
    • (2012) Clin. Cancer Res. , vol.18 , pp. 2056-2065
    • Hayes, D.N.1
  • 49
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • Prahallad A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1
  • 50
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • Corcoran R.B., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
    • (2012) Cancer Discov. , vol.2 , pp. 227-235
    • Corcoran, R.B.1
  • 51
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
    • (2011) Nature , vol.480 , pp. 387-390
    • Poulikakos, P.I.1
  • 52
    • 52149115126 scopus 로고    scopus 로고
    • ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
    • Li X., et al. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 2008, 20:2145-2155.
    • (2008) Cell. Signal. , vol.20 , pp. 2145-2155
    • Li, X.1
  • 53
    • 84863596086 scopus 로고    scopus 로고
    • MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
    • Turke A.B., et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012, 72:3228-3237.
    • (2012) Cancer Res. , vol.72 , pp. 3228-3237
    • Turke, A.B.1
  • 54
    • 80555157475 scopus 로고    scopus 로고
    • Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
    • Ebi H., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 2011, 121:4311-4321.
    • (2011) J. Clin. Invest. , vol.121 , pp. 4311-4321
    • Ebi, H.1
  • 55
    • 84877630250 scopus 로고    scopus 로고
    • Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer
    • Molina-Arcas M., et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013, 3:548-563.
    • (2013) Cancer Discov. , vol.3 , pp. 548-563
    • Molina-Arcas, M.1
  • 56
    • 84888125634 scopus 로고    scopus 로고
    • Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models
    • Flanigan S.A., et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin. Cancer Res. 2013, 19:6219-6229.
    • (2013) Clin. Cancer Res. , vol.19 , pp. 6219-6229
    • Flanigan, S.A.1
  • 57
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos P.I., et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1
  • 58
    • 77949685981 scopus 로고    scopus 로고
    • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • Hatzivassiliou G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
    • (2010) Nature , vol.464 , pp. 431-435
    • Hatzivassiliou, G.1
  • 59
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn S.J., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1
  • 60
    • 84877825519 scopus 로고    scopus 로고
    • RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation
    • Holderfield M., et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 2013, 23:594-602.
    • (2013) Cancer Cell , vol.23 , pp. 594-602
    • Holderfield, M.1
  • 61
    • 84879795966 scopus 로고    scopus 로고
    • Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma
    • Gibney G.T., et al. Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 2013, 10:390-399.
    • (2013) Nat. Rev. Clin. Oncol. , vol.10 , pp. 390-399
    • Gibney, G.T.1
  • 62
    • 84871037064 scopus 로고    scopus 로고
    • Progression of RAS-mutant leukemia during RAF inhibitor treatment
    • Callahan M.K., et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 2012, 367:2316-2321.
    • (2012) N. Engl. J. Med. , vol.367 , pp. 2316-2321
    • Callahan, M.K.1
  • 63
    • 84897142154 scopus 로고    scopus 로고
    • BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling
    • Sanchez-Laorden B., et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 2014, 7:ra30.
    • (2014) Sci. Signal. , vol.7 , pp. ra30
    • Sanchez-Laorden, B.1
  • 64
    • 84898023140 scopus 로고    scopus 로고
    • Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
    • Sun C., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014, 7:86-93.
    • (2014) Cell Rep. , vol.7 , pp. 86-93
    • Sun, C.1
  • 65
    • 84900442808 scopus 로고    scopus 로고
    • Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tTumors
    • Lito P., et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tTumors. Cancer Cell 2014, 25:697-710.
    • (2014) Cancer Cell , vol.25 , pp. 697-710
    • Lito, P.1
  • 66
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    • Engelman J.A., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
    • (2008) Nat. Med. , vol.14 , pp. 1351-1356
    • Engelman, J.A.1
  • 67
    • 84874613332 scopus 로고    scopus 로고
    • Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
    • Posch C., et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4015-4020.
    • (2013) Proc. Natl. Acad. Sci. U.S.A. , vol.110 , pp. 4015-4020
    • Posch, C.1
  • 68
    • 84871183627 scopus 로고    scopus 로고
    • A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors
    • LoRusso P., et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30(15_Suppl):2566.
    • (2012) J. Clin. Oncol. , vol.30 , Issue.15 SUPPL , pp. 2566
    • LoRusso, P.1
  • 69
    • 84899048311 scopus 로고    scopus 로고
    • Pharmacodynamic biomarker-driven trial of MK-2206, and AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma
    • Speranza G., et al. Pharmacodynamic biomarker-driven trial of MK-2206, and AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma. J. Clin. Oncol. 2012, 30(15_Suppl):3529.
    • (2012) J. Clin. Oncol. , vol.30 , Issue.15 SUPPL , pp. 3529
    • Speranza, G.1
  • 70
    • 84859765844 scopus 로고    scopus 로고
    • Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
    • Duncan J.S., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
    • (2012) Cell , vol.149 , pp. 307-321
    • Duncan, J.S.1
  • 71
    • 84869067183 scopus 로고    scopus 로고
    • Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
    • Lito P., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
    • (2012) Cancer Cell , vol.22 , pp. 668-682
    • Lito, P.1
  • 72
    • 84861381332 scopus 로고    scopus 로고
    • Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
    • Basile K.J., et al. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 2012, 31:2471-2479.
    • (2012) Oncogene , vol.31 , pp. 2471-2479
    • Basile, K.J.1
  • 73
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
    • (2012) Nature , vol.487 , pp. 500-504
    • Straussman, R.1
  • 74
    • 84864286442 scopus 로고    scopus 로고
    • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
    • Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
    • (2012) Nature , vol.487 , pp. 505-509
    • Wilson, T.R.1
  • 75
    • 84897531613 scopus 로고    scopus 로고
    • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
    • Sun C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
    • (2014) Nature , vol.508 , pp. 118-122
    • Sun, C.1
  • 76
    • 84869499716 scopus 로고    scopus 로고
    • Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
    • Seghers A.C., et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012, 22:466-472.
    • (2012) Melanoma Res. , vol.22 , pp. 466-472
    • Seghers, A.C.1
  • 77
    • 84873728334 scopus 로고    scopus 로고
    • Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    • Das Thakur M., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
    • (2013) Nature , vol.494 , pp. 251-255
    • Das Thakur, M.1
  • 78
    • 0942287932 scopus 로고    scopus 로고
    • Effect of re-treatment with gefitinib ('Iressa' ZD1839) after acquisition of resistance
    • Kurata T., et al. Effect of re-treatment with gefitinib ('Iressa' ZD1839) after acquisition of resistance. Ann. Oncol. 2004, 15:173-174.
    • (2004) Ann. Oncol. , vol.15 , pp. 173-174
    • Kurata, T.1
  • 79
    • 20444456682 scopus 로고    scopus 로고
    • Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases
    • Yano S., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res. 2005, 15:107-111.
    • (2005) Oncol. Res. , vol.15 , pp. 107-111
    • Yano, S.1
  • 80
    • 80155142474 scopus 로고    scopus 로고
    • Rapamycin passes the torch: a new generation of mTOR inhibitors
    • Benjamin D., et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
    • (2011) Nat. Rev. Drug Discov. , vol.10 , pp. 868-880
    • Benjamin, D.1
  • 81
    • 0035970744 scopus 로고    scopus 로고
    • The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors
    • Stein E.G., et al. The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors. FEBS Lett. 2001, 493:106-111.
    • (2001) FEBS Lett. , vol.493 , pp. 106-111
    • Stein, E.G.1
  • 82
    • 79958696336 scopus 로고    scopus 로고
    • Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling
    • Yu Y., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
    • (2011) Science , vol.332 , pp. 1322-1326
    • Yu, Y.1
  • 83
    • 79958696694 scopus 로고    scopus 로고
    • The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
    • Hsu P.P., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
    • (2011) Science , vol.332 , pp. 1317-1322
    • Hsu, P.P.1
  • 84
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly K.E., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
    • (2006) Cancer Res. , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1
  • 85
    • 80655126355 scopus 로고    scopus 로고
    • MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    • Rodrik-Outmezguine V.S., et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
    • (2011) Cancer Discov. , vol.1 , pp. 248-259
    • Rodrik-Outmezguine, V.S.1
  • 86
    • 78651458656 scopus 로고    scopus 로고
    • AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    • Chandarlapaty S., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
    • (2011) Cancer Cell , vol.19 , pp. 58-71
    • Chandarlapaty, S.1
  • 87
    • 79957917078 scopus 로고    scopus 로고
    • PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    • Serra V., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
    • (2011) Oncogene , vol.30 , pp. 2547-2557
    • Serra, V.1
  • 88
    • 84856989746 scopus 로고    scopus 로고
    • Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
    • Muranen T., et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
    • (2012) Cancer Cell , vol.21 , pp. 227-239
    • Muranen, T.1
  • 89
    • 84897033468 scopus 로고    scopus 로고
    • Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
    • Ducker G.S., et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014, 33:1590-1600.
    • (2014) Oncogene , vol.33 , pp. 1590-1600
    • Ducker, G.S.1
  • 90
    • 51349164790 scopus 로고    scopus 로고
    • Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    • Carracedo A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
    • (2008) J. Clin. Invest. , vol.118 , pp. 3065-3074
    • Carracedo, A.1
  • 91
    • 84894557306 scopus 로고    scopus 로고
    • Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
    • Will M., et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014, 4:334-347.
    • (2014) Cancer Discov. , vol.4 , pp. 334-347
    • Will, M.1
  • 92
    • 84869194238 scopus 로고    scopus 로고
    • Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
    • Grabinski N., et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol. Cancer 2012, 11:85.
    • (2012) Mol. Cancer , vol.11 , pp. 85
    • Grabinski, N.1
  • 93
    • 84906238910 scopus 로고    scopus 로고
    • Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
    • Passacantilli I., et al. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget 2014, 5:5381-5391.
    • (2014) Oncotarget , vol.5 , pp. 5381-5391
    • Passacantilli, I.1
  • 94
    • 84868628069 scopus 로고    scopus 로고
    • Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
    • McCubrey J.A., et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012, 3:954-987.
    • (2012) Oncotarget , vol.3 , pp. 954-987
    • McCubrey, J.A.1
  • 95
    • 84872387485 scopus 로고    scopus 로고
    • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
    • Corcoran R.B., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
    • (2013) Cancer Cell , vol.23 , pp. 121-128
    • Corcoran, R.B.1
  • 96
    • 78649729548 scopus 로고    scopus 로고
    • Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
    • Meng J., et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE 2010, 5:e14124.
    • (2010) PLoS ONE , vol.5
    • Meng, J.1
  • 97
    • 84922485593 scopus 로고    scopus 로고
    • RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
    • Simona L., et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 2014, 10.1016/j.celrep.2014.07.033.
    • (2014) Cell Rep.
    • Simona, L.1
  • 98
    • 84905007559 scopus 로고    scopus 로고
    • Combined inhibition of BRAF and MEK in melanoma patients
    • Infante J.R., Swanton C. Combined inhibition of BRAF and MEK in melanoma patients. Lancet Oncol. 2014, 15:908-910.
    • (2014) Lancet Oncol. , vol.15 , pp. 908-910
    • Infante, J.R.1    Swanton, C.2
  • 99
    • 55949096610 scopus 로고    scopus 로고
    • Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines
    • Grueneberg D.A., et al. Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16490-16495.
    • (2008) Proc. Natl. Acad. Sci. U.S.A. , vol.105 , pp. 16490-16495
    • Grueneberg, D.A.1
  • 100
    • 55949117661 scopus 로고    scopus 로고
    • Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
    • Grueneberg D.A., et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16472-16477.
    • (2008) Proc. Natl. Acad. Sci. U.S.A. , vol.105 , pp. 16472-16477
    • Grueneberg, D.A.1
  • 101
    • 84919393400 scopus 로고    scopus 로고
    • Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
    • abstr
    • Van Geel R., et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J. Clin. Oncol. 2014, 32(5s, suppl):3514. abstr.
    • (2014) J. Clin. Oncol. , vol.32 , Issue.5 , pp. 3514
    • Van Geel, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.